Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

50.50USD
4:01pm EDT
Change (% chg)

$-0.19 (-0.37%)
Prev Close
$50.69
Open
$50.91
Day's High
$50.91
Day's Low
$50.14
Volume
1,372,939
Avg. Vol
1,389,867
52-wk High
$51.72
52-wk Low
$39.28

ABT.N

Chart for ABT.N

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $75,465.11
Shares Outstanding(Mil.): 1,488.76
Dividend: 0.24
Yield (%): 1.89

Financials

  ABT.N Industry Sector
P/E (TTM): 32.16 37.25 40.68
EPS (TTM): 1.58 -- --
ROI: -- 16.52 15.78
ROE: -- 17.30 16.82
Search Stocks

Abbott strikes deals with heart valve replacement companies

- Abbott Laboratories on Thursday said it would buy a small private company and has invested in another, with an option to buy, as it places bets on the future growth potential of minimally invasive systems to replace diseased heart valves.

30 Jul 2015

UPDATE 1-Abbott strikes deals with heart valve replacement companies

July 30 - Abbott Laboratories on Thursday said it would buy a small private company and has invested in another, with an option to buy, as it places bets on the future growth potential of minimally invasive systems to replace diseased heart valves.

30 Jul 2015

Abbott strikes deals with heart valve replacement companies

July 30 - Abbott Laboratories on Thursday said it would buy a small private company and has invested in another, with an option to buy, as it places bets on the future growth potential of minimally invasive systems to replace diseased heart valves.

30 Jul 2015

BRIEF-Abbott announces two Mitral valve transactions

* Abbott says will acquire the equity of Tendyne that it does not already own for $225 million upfront

30 Jul 2015

UPDATE 1-India expands medicine price control list to include 39 more drugs

* Abbott, GSK, Lupin and Ipca among firms affected (Adds details on government's position, results of new study )

16 Jul 2015

Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source

TEL AVIV, June 23 - Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said.

23 Jun 2015

Teva raises stake in Mylan as three-way takeover battle heats up

- Israel's Teva Pharmaceutical Industries Ltd has raised its stake in Mylan N.V. to the 4.61 percent needed for it to legally challenge Mylan's rejection of Teva's hostile takeover offer under Dutch law.

19 Jun 2015

Abbott to vote for Mylan's acquisition of Perrigo

- Mylan NV's largest stakeholder, Abbott Laboratories , said it would back Mylan's proposed acquisition of Perrigo Co Plc , potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .

16 Jun 2015

REFILE-UPDATE 1-Abbott to vote for Mylan's acquisition of Perrigo

June 16 - Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .

16 Jun 2015

PRESS DIGEST- New York Times business news - May 26

May 26 - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.

26 May 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $100.02 -0.19
Pfizer Inc. (PFE.N) $36.15 +0.09
Novartis AG (NOVN.VX) CHF101.10 +0.70
Merck & Co., Inc. (MRK.N) $59.05 +0.09
Sanofi SA (SASY.PA) €98.64 +0.67
AstraZeneca plc (AZN.L) 4,342.00p +22.00
GlaxoSmithKline plc (GSK.L) 1,400.00p +4.00
Eli Lilly and Co (LLY.N) $84.14 -0.37
Amgen, Inc. (AMGN.OQ) $175.59 -1.00
Boston Scientific Corporation (BSX.N) $17.11 -0.23

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$49.00
Provider : GlobalData
$125.00
Provider : ValuEngine, Inc.
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks